<DOC>
	<DOCNO>NCT01967602</DOCNO>
	<brief_summary>The goal project find marker expression investigator use trace symptom progression develop efficient therapy enhance ARDS patient survival rate well post-ICU life quality .</brief_summary>
	<brief_title>Biomarker Lung Injury ARDS Patients Receiving ECMO Support</brief_title>
	<detailed_description>The investigator first identify acute respiratory distress syndrome ( ARDS ) patient receive ECMO support ICU National Taiwan University Hospital , collect blood , urine bronchioalveolar lavage fluid ( BALF ) sample different time point : setting ECMO , 2 , 6 , 12 , 24 , 72 hours,5 14 day ECMO installment , time wean ECMO day remove ECMO leave ICU . From sample , free radical , cytokine ( IL-1 , IL-6 , IL-8 , IL-18 , tumor necrosis factor-α , transform growth factor-β ) , inflammasome- related marker , immune cell responses biochemical marker would measure . The novel biomarkers predict outcome patient identify .</detailed_description>
	<mesh_term>Lung Injury</mesh_term>
	<mesh_term>Multiple Organ Failure</mesh_term>
	<criteria>1 . &gt; 18 year old 2 . ARDS , need ECMO support 1. preexist sepsis 2. preexisting chronic renal failure ( dialysis dependent ) , liver failure diseases preclude chance survival .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Acute respiratory distress syndrome ( ARDS )</keyword>
	<keyword>Extracorporeal membrane oxygenation ( ECMO )</keyword>
	<keyword>biomarker</keyword>
</DOC>